Progyny Inc (PGNY) Stock Down 3.8% -- Now Undervalued? GF Score: 87/100
On May 21, 2026, Progyny Inc (PGNY) shares fell 3.8%, closing at $24.69. This decline comes amidst a 52-week range where the stock has seen a high of $28.75 and
PGNY - Progyny, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$30.33
DETAILS
HIGH:
$35.00
LOW:
$27.00
MEDIAN:
$30.00
CONSENSUS:
$30.33
UPSIDE:
21.91%
Stock News
Progyny, Inc. (PGNY) Shareholder/Analyst Call Transcript
Progyny, Inc. (PGNY) Shareholder/Analyst Call Transcript
Bull of the Day: Progyny (PGNY)
For growth investors seeking exposure to a differentiated healthcare disruptor with strong secular tailwinds, Progyny (PGNY) stock deserves a close look.
Progyny, Inc. (PGNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Progyny, Inc. (PGNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
3 Highly Ranked Medical Stocks to Buy Now: DVA, GMED, PGNY
These highly ranked medical stocks have been capitalizing on their sales expansion, and their defensive or secular growth profiles could become even more attractive if an economic downturn emerges.
Progyny, Inc. to Present at BofA Securities 2026 Health Care Conference
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that Progyny's Chief Executive Officer, Pete Anevski, and Chief Financial Officer, Mark Livingston, will participate in a fireside chat at the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026, at 11:20 A.M. Pacific Time / 2:20 P.M. Eastern Time.
Progyny Q1 Earnings Call Highlights
Progyny NASDAQ: PGNY reported what management called a strong start to 2026, with first-quarter revenue reaching a record level and profitability exceeding expectations amid continued investments in its platform and member experience.
Progyny, Inc. (PGNY) Q1 2026 Earnings Call Transcript
Progyny, Inc. (PGNY) Q1 2026 Earnings Call Transcript
Progyny (PGNY) Q1 Earnings and Revenues Beat Estimates
Progyny (PGNY) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.48 per share a year ago.
Progyny, Inc. Announces First Quarter 2026 Results
Reports Record First Quarter Revenue of $328.5 MillionEarly Selling Season Activity Reflects Robust Demand for Women's Health and Family Building SolutionsReturned Value to Shareholders Through Repurchase of 8.8 Million Shares to Date Since November NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended March 31, 2026 (“the first quarter of 2026”), as compared to the three-month period ended March 31, 2025 (“the first quarter of 2025” or “the prior year period”). “We're pleased with the strong start to the year, as member engagement trended to the higher end of our expectations, reflecting that people are pursuing the services they need in order to address their family building and overall health and well-being goals,” said Pete Anevski, Chief Executive Officer of Progyny.
Should Value Investors Buy Progyny (PGNY) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Progyny (PGNY) Upgraded to Buy: Here's Why
Progyny (PGNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PGNY or ALHC: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical Services stocks have likely encountered both Progyny (PGNY) and Alignment Healthcare (ALHC). But which of these two stocks is more attractive to value investors?
Progyny, Inc. (NASDAQ:PGNY) Receives Consensus Rating of “Moderate Buy” from Analysts
Progyny, Inc. (NASDAQ: PGNY - Get Free Report) has been given an average recommendation of "Moderate Buy" by the thirteen analysts that are presently covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month target
Progyny, Inc. Announces Details for Its First Quarter 2026 Results Report
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period ended March 31, 2026, after the close of the market on Thursday, May 7, 2026.
Progyny, Inc. Announces Details for Its First Quarter 2026 Results Report
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period ended March 31, 2026, after the close of the market on Thursday, May 7, 2026.
Progyny Expands Access to Fertility and Women's Health with Industry's First Fully Insured Supplemental Plan
NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announces Progyny Select, the industry's first fully insured, comprehensive supplemental fertility and family building plan. Available in the U.S., Progyny Select enables small employers to have access to fertility solutions in a fixed premium model.
Progyny Inc (PGNY) Shares Surge 4.2% -- What GF Score of 88 Tells Investors
On April 13, 2026, Progyny Inc (PGNY) shares rose 4.2% to a current price of $16.98. The stock has traded between $16.10 and $28.75 over the past 52 weeks, refl
Reviewing Progyny (NASDAQ:PGNY) & Surgery Partners (NASDAQ:SGRY)
Progyny (NASDAQ: PGNY - Get Free Report) and Surgery Partners (NASDAQ: SGRY - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation. Analyst Ratings This is a summary of current
Progyny Commemorates 10 Years of Redefining Women's Health and Family Building Care
Throughout 2026, in partnership with members, providers, and employers, Progyny will highlight a decade of innovation, expanded access, and industry-leading outcomes. Throughout 2026, in partnership with members, providers, and employers, Progyny will highlight a decade of innovation, expanded access, and industry-leading outcomes.
Price Targets
Progyny upgraded to Buy from Hold at Canaccord
$30.00
(was $24.05)
Canaccord Genuity
Progyny price target raised to $27 from $23 at Barclays
$27.00
(was $23.25)
Barclays
Progyny (PGNY) PT Lowered to $30 at Jefferies
$30.00
(was $17.79)
Brian Tanquilut
·
Jefferies
Progyny (PGNY) PT Lowered to $28 at Truist Securities
$28.00
(was $17.69)
Jailendra Singh
·
Truist Financial
Progyny price target raised to $35 from $30 at BTIG
$35.00
(was $25.28)
J.P. Morgan
Progyny upgraded to Buy from Hold at Truist
$34.00
(was $28.23)
Jailendra Singh
·
Truist Financial
Progyny price target raised to $32 from $30 at KeyBanc
$32.00
(was $26.80)
Scott Schoenhaus
·
KeyBanc
Progyny initiated with an Overweight at Barclays
$29.00
(was $24.70)
Peter Warendorf
·
Barclays
KeyBanc upgrades Progyny to Overweight on 'emerging' catalysts
$30.00
(was $23.81)
KeyBanc
Cantor Fitzgerald Reiterates Overweight Rating on Progyny (PGNY)
$28.00
(was $22.22)
Sarah James
·
Raymond James
Progyny price target raised to $27 from $24 at Truist
$27.00
(was $23.05)
Jailendra Singh
·
Truist Financial
Progyny price target raised to $23 from $17 at Canaccord
$23.00
(was $22.53)
Canaccord Genuity
Progyny (PGNY) PT Lowered to $19 at Jefferies
$19.00
(was $21.61)
Glen Santangelo
·
Jefferies
Progyny (PGNY) PT Lowered to $22 at Cantor Fitzgerald
$22.00
(was $21.61)
Sarah James
·
Cantor Fitzgerald
Truist Securities Downgrades Progyny (PGNY) to Hold
$19.00
(was $21.61)
Jailendra Singh
·
Truist Financial
Progyny (PGNY) PT Lowered to $18 at Canaccord Genuity
$18.00
(was $16.46)
Richard Close
·
Canaccord Genuity
Progyny (PGNY) PT Lowered to $22 at BofA Securities
$22.00
(was $16.46)
Michael Cherny
·
Bank of America Securities
Jefferies lowers Progyny price target to $24, calls selloff 'excessive'
$24.00
(was $16.55)
Glen Santangelo
·
Jefferies
Progyny (PGNY) PT Raised to $33 at Truist Securities
$33.00
(was $17.78)
Jailendra Singh
·
Truist Financial
Canaccord Genuity Downgrades Progyny (PGNY) to Hold
$24.00
(was $25.74)
Richard Close
·
Canaccord Genuity